Biotechnology

As Orca Bio builds a manufacturing empire from Sacramento to Princeton, it's not just preparing for a new drug launch—it's trying to solve the biggest puzzle in biotech.

A new study offers hope for MS by promoting nerve repair, but the real story is the validation of a versatile stem cell platform for a new era of medicine.

New data reveals elevated cortisol in over 75% of hard-to-treat diabetes patients, paving the way for a novel drug to tackle treatment resistance.

Facing a 'going concern' warning and collapsing revenue, Splash Beverage Group is ditching drinks for drugs. Its investment in Avicanna is a desperate, yet strategic, pivot.

Fate Therapeutics' new board appointment signals a major shift. Can a commercial veteran turn groundbreaking iPSC science into accessible, off-the-shelf medicine?

For decades, patients with advanced chondrosarcoma had no options. Now, a new drug's journey to the FDA offers a lifeline and a lesson in medical neglect.

A single AML patient's journey to a stem cell transplant after treatment with CER-1236 offers a glimmer of hope, but is it a breakthrough or a mirage?

Legend Biotech's stunning trial results for an 'in vivo' CAR-T therapy could make advanced cancer treatment faster, safer, and accessible to all.

Biocytogen's new 'gold standard' accreditation isn't just about animal welfare. It's a calculated move to de-risk drug development and win global partners.

While CEO Craig Chambliss's EY award makes headlines, the real story is Neurelis's disruption of epilepsy care and its ambitious pipeline for brain disorders.

Phase 1 data for Marea Therapeutics’ MAR002 suggests a potential new era for acromegaly treatment, promising better control with far fewer injections.

With a landmark therapy for Sanfilippo Syndrome nearing the FDA, Spruce adds veteran marketing and finance chiefs. A look at the talent behind the transition.

A new, single-shot vaccine for dogs targets two spreading diseases. This innovation aims to make vet visits less stressful and close critical health gaps.

Elysium Health's new Creatine+ isn't just a supplement; it's a signal of a massive structural shift where human vitality becomes a core economic asset.

A world-first treatment in Canada saved a young burn victim's face, bypassing devastating grafts. But can this 'miracle' therapy move from one-off to standard care?

Alexandria Real Estate's top WSJ ranking for talent readiness reveals a new playbook where human capital is the most valuable asset, even in real estate.

Amid new Ebola fears, one biotech's rapid C1 platform promises 15-day biologics, eyeing a $25B market beyond just pandemic response. But can it deliver?

Formerly Hoth Therapeutics, Rocket One is betting its future on novel spintronic computing. A look at the tech, the risks, and the ambitious strategy.

As 250 million people await a drug for lymphatic diseases, Celltaxis appoints a new CEO to drive its promising inflammation-targeting therapy toward the finish line.

Tiziana Life Sciences’ chairman just increased his massive stake. We analyze if this is a vote of confidence in its novel MS drug or a risky bet on a fragile biotech.